Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC)

T. Inaba, M. Mizuno, S. Ohya, M. Kawada, T. Uesu, J. Nasu, K. Takeuchi, M. Nakagawa, H. Okada, T. Fujita, T. Tsuji

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


Colonic epithelial cells of patients with UC express DAF in relation to the severity of mucosal inflammation. The aim of this study was to determine whether this factor in stool could be used as a marker of disease activity in UC patients. Stool DAF was measured by use of an immunoassay in 181 stool specimens obtained from 55 patients with UC of various levels of disease activity. Stool DAF concentrations in patients whose UC was active (0.0- 785.6 ng/g stool: median 47.1 ng/g; n = 115) were significantly higher than concentrations in patients whose disease was inactive (0.0-48.6 ng/g; median 0.0 ng/g; n=66) (P<0.0001). Values in active UC patients also were higher than those in control patients with diarrhoea (0.0-30.0 ng/g; median 0.0 ng/g; n =26) (P<0.0001) and in control subjects without apparent colorectal disease (0-20.4 ng/g; median 0.0 ng/g; n = 44) (P < 0.0001). The elevated levels of stool DAF obtained from UC patients in relapse declined markedly in specimens collected after the disease went into remission following medical therapy. Stool DAF levels correlated with the severity of endoscopic and histological findings and the degree of DAF expression on the colonic epithelia. Our results suggest that the measurement of stool DAF is useful as a non-invasive means of monitoring intestinal disease activity in patients with UC.

Original languageEnglish
Pages (from-to)237-241
Number of pages5
JournalClinical and Experimental Immunology
Issue number2
Publication statusPublished - 1998


  • CD55
  • Decay-accelerating factor
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC)'. Together they form a unique fingerprint.

Cite this